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Abstract
Background: Caffeine intake is generally estimated by self-reported consumption, but it remains unclear how well
self-report associates with metabolite urinary excretion. We investigated the associations of self-reported consumption
of caffeinated drinks with urinary excretion of caffeine and its major metabolites in an adult population.
Methods: We used data from the population-based Swiss Kidney Project on Genes in Hypertension (SKIPOGH) study.
Consumption of caffeinated coffee, decaffeinated coffee and other caffeinated beverages was assessed by self-
administered questionnaire. Quantification of caffeine, paraxanthine, theobromine and theophylline was performed by
ultra-high performance liquid chromatography tandem mass spectrometry in 24-h urine. Association of reported
consumption of caffeinated drinks with urinary caffeine derived metabolites was determined by quantile regression.
We then explored the association between urinary metabolite excretion and dichotomized weekly consumption
frequency of caffeinated coffee, with Receiver Operator Characteristic (ROC) analysis.
Results: In the present analysis, we included 598 individuals (52% women, mean age =46 ± 17 years). Self-reported
caffeinated coffee intake was positively associated with 24-h urinary excretions of paraxanthine, theophylline and
caffeine (p < 0.001), whereas reported intakes of decaffeinated coffee and other caffeinated beverages showed no
association. In ROC analysis, optimal discrimination between individuals consuming less than one caffeinated coffee/
week, vs. at least one coffee, was obtained for 24-h urinary paraxanthine (Area Under Curve (AUC) = 0.868, 95%
Confidence Interval (CI) [0.830;0.906]), with slightly lower performance for theophylline and caffeine, whereas
theobromine did not allow any discrimination.
Conclusion: Our results suggest that reported consumption of caffeinated coffee is positively associated with 24-h
urinary excretion of caffeine, paraxanthine, and theophylline, and may be used as a marker of caffeine intake for
epidemiological studies.
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Background
Coffee is one of the most widely consumed beverages in
the world and the source of more than 1000 biologically
active compounds [1] such as alkaloids, polyphenols,
diterpene alcohols and others. The most abundant bio-
logically active molecule in coffee is caffeine, a purine
alkaloid, which is also found in soft drinks, tea and
numerous other food items [2, 3]. More than 70% of caf-
feine is provided by caffeinated coffee consumption, and
then metabolized by the liver CYP1A2 enzyme into para-
xanthine (~80%), theobromine (~12%) and theophylline
(~4%) [4]. Caffeine and caffeine related metabolites belong
to the group of methylxanthines: a family of nonspecific
adenosine receptor antagonists with several physiological
properties, including diuresis and natriuresis [5, 6]. Due to
caffeine’s virtual omnipresence in human diet, the health
consequences of coffee and caffeine consumption are of
major interest. While acute coffee and caffeine intake acti-
vate sympathomimetic effects such as increased blood
pressure [7] and lipolysis [8], recent epidemiological stud-
ies suggested that chronic coffee and caffeine intake may
exert beneficial long-term health effects by reducing the
risk of chronic diseases such as type 2 diabetes, cardiovas-
cular disease (CVD), some types of cancer [9], and even
mortality [10, 11].
A key step in understanding coffee- or caffeine-
associated health outcomes consists in accurately asses-
sing individual’s exposure to these compounds.
Population-based studies are mainly relying on question-
naires, which collect self-reported information on the
quantity, frequency and the type of intake [12–14]. Al-
though these questionnaires provide valuable epidemio-
logical information, they remain approximate and
subject to meaningful misclassification/measurement
bias [15]. Validation by comparison with 24-h dietary re-
calls, daily diary records [16, 17] or 24-h excretion of
specific biomarkers [18] are needed. Regarding caffeine
intake, objective data are still lacking. Only a limited
number of studies have compared self-reported con-
sumption of different caffeinated beverages and caffeine
with urinary excretion of caffeine metabolites [19] or
with other biological material [20, 21], and no such asso-
ciations have yet been investigated in large population-
based studies.
In the present work, we compared self-reported con-
sumption of coffee and other caffeinated beverages with
24-h urinary excretions of caffeine, a validated biological
marker of caffeine intake [19, 22], and its metabolites in
the Swiss Kidney Project on Genes in Hypertension
(SKIPOGH) cohort. The SKIPOGH study is of particular
interest regarding this association, as it extensively inves-
tigates both genetic and environmental determinants of
blood pressure, including caffeine intake through self-
report as well as 24-h urinary excretion measures [4].
Methods
Study population and design
We used data from the SKIPOGH project, a family and
population-based cross-sectional study exploring genetic
and environmental determinants of blood pressure. Par-
ticipants were recruited from December 2009 until April
2013 in the Swiss cities of Lausanne, Geneva and Bern
as previously described [23, 24]. Inclusion criteria were:
(1) written informed consent; (2) minimum age of
18 years; (3) Caucasian origin, defined as having both
parents and grandparents born in a restricted list of
countries; (4) at least one, and preferably three, first-
degree family members also willing to participate.
Women who reported being pregnant were excluded
from the SKIPOGH study. All included participants sus-
tained a morning medical visit after an overnight fast,
completed a self-administered life/medical history ques-
tionnaire and were asked to collect urine over 24-h. All
participants signed written informed consent. The total
study population included 1128 participants coming
from 273 nuclear families.
Clinical and biological data
Participants came for the study visit at one of the three
medical centers, and filled in a standardized question-
naire at home. The questionnaire focused on a variety of
issues including lifestyle habits as well as medical his-
tory. Body weight (kg), height (cm) and waist and hip
circumferences (cm) were measured according to stand-
ard procedures. Body mass index (BMI) was defined as
weight in kg divided by height in meters squared. Ven-
ous blood samples were drawn while fasting. Kidney
function and other biological markers were measured in
local university laboratories using standard clinical la-
boratory methods. The collection of 24-h urine sample
was previously described [23, 25, 26]. Smoking status
was categorized as current and noncurrent smokers, the
latter category including never smokers and ex-smokers.
Alcohol consumption was defined as consuming more
than one alcoholic beverage per week (“Yes” or “No”).
Caffeinated beverages frequency questionnaire
Caffeinated beverages frequency questionnaire, presented
in the Appendix, was used to assess caffeine exposure
through reported consumption of caffeinated beverages,
and was based on a literature review of dietary question-
naires used in Europe as well as on cultural aspects of caf-
feinated beverage consumption in Switzerland [27–29].
The SKIPOGH questionnaire on caffeinated beverages
was prospectively introduced in the second period of
study recruitment and submitted to 657 participants
(58%). We considered three major items; 1) caffeinated
coffee, 2) decaffeinated coffee, and 3) other caffeinated
beverages (soft drinks, energy drinks, black or green tea).
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For each item, consumption frequency was assessed
through the question “How often do you consume caffein-
ated coffee/decaffeinated coffee/caffeinated beverages
other than coffee?”), with five possible answers: “Never”;
“1–4 beverages/month”, “1–4 beverages/week”, “≥5 bever-
ages a week”, “≥1 beverage/day”. Moreover, individuals
who reported consuming ≥1caffeinated coffee per day also
reported the number of daily cups. The questionnaire also
reported the time and quantity of the last beverage con-
sumed before blood was drawn.
Urinary caffeine metabolites
Caffeine (urine and plasma), paraxanthine (urine and
plasma), theobromine (urine) and theophylline (urine)
were quantified by ultra-high performance liquid chro-
matography (Waters ACQUITY UPLC I-Class for urine
and Waters ACQUITY UPLC for plasma) coupled to
electrospray ionization-tandem mass spectrometry
(Waters Xevo TQ-S for urine and Waters TQD for
plasma). Sample preparation was performed by simple di-
lution for urine and protein precipitation for plasma. Limit
of quantification in urine was 10 ng/ml for caffeine, para-
xanthine and theophylline and 20 ng/ml for theobromine,
and in plasma was 5 ng/ml for caffeine and paraxanthine.
The methods were fully validated according to the latest
international guidelines using a stable isotope-labeled
internal standard for each analyte. Expanded uncertainty
(95% confidence level) calculated during routine use was
8.2, 7.6, 7.8 and 8.1% for caffeine, paraxanthine, theobro-
mine and theophylline in urine, respectively, and 9.4 and
10.5% for caffeine and paraxanthine in plasma, respect-
ively (Ansermot et al. manuscript in preparation, detailed
method available on request).
Statistical analyses
Continuous variables were described with median or
mean and standard deviation. Categorical variables were
described with percentages. Twenty-four hours urinary
caffeine, paraxanthine, theophylline and theobromine
were winsorised to exclude extreme outliers (99th per-
centile) as performed previously [30–32]. We used quan-
tile regression to explore the association between
reported consumption frequency of caffeinated coffee,
other caffeinated beverages and decaffeinated coffee, and
caffeine metabolites, within a non-adjusted model and a
model adjusted for major confounders. Variables in-
cluded in the fully adjusted model as potential con-
founders were a priori considered, given their reported
or potential influence on caffeine intake and urinary caf-
feine and paraxanthine excretion [14]. The following
confounding variables were included: age, sex, BMI,
Chronic Kidney Disease-Epidemiology Collaboration
Formula (CKD-EPI) for glomerular filtration rate (GFR),
as well as current smoking and alcohol use. Creatinine
excretion per body weight (mg/kg/24-h), urinary volume
(ml) and/or urinary flow (ml/min) were used as covari-
ates in the fully adjusted model to account for the qual-
ity of urine collection. The full-model was also adjusted
for center to take into account the potential clustering
of caffeine metabolites excretion [14]. Familial correla-
tions were taken into account for all analyses. Statistical
significances for association were set at a p-value <0.05.
To further quantify the degree of association between
reported consumption frequency of the three types of
beverages and caffeine-derived urinary metabolites, we
also performed a spearman correlation (ρ) analysis for
the unadjusted model. All statistical analyses were
conducted using STATA 14.0 (Stata Corp, Stata College
Station, Texas, USA).
Receiver operator characteristic analysis
To further explore the association between self-reported
consumption frequency and 24-h urinary metabolites,
we performed a Receiver Operator Characteristic (ROC)
analysis between dichotomized consumption frequency
of caffeinated coffee and 24-h urinary caffeine, para-
xanthine, theophylline and theobromine. The ROC ana-
lyses were performed whenever the quantitative regression
between self-reported consumption frequency and 24-h
urinary excretion was significant. The dichotomized
threshold based on the self-reported consumption fre-
quency was defined as following: Less than one caffeinated
coffee per week : “Never”, “1–4×/month”; At least one caf-
feinated coffee per week: “1–4×/week”, “≥5×/week”, “≥1×/
day”. This threshold was chosen based on the results from
preliminary ROC analysis of all different possible dichot-
omous thresholds.
We computed 95% confidence intervals (CI) for Area
Under Curves (AUC) for the 24-h urinary caffeine, para-
xanthine, theophylline and theobromine. Optimal sensi-
tivity and specificity values were determined according
to Youden index in ROC analysis [33].
Results
Out of the 657 SKIPOGH participants who completed
the caffeine beverages questionnaire, 598 participants
(48% men) had no missing data on beverage frequency
intake, 24-h metabolite excretion as well as other covari-
ates, and were included in the study. Participants who
were included in the analysis tended to be younger, had
a slightly higher alcohol intake and were mainly re-
cruited in Geneva and Lausanne.
We summarize the main characteristics of the sample
according to sex in Table 1. Women had a lower BMI, a
lower 24-h urinary creatinine, a lower 24-h urinary para-
xanthine excretion, were less frequently smokers, con-
sumed less frequently one or more alcoholic drink per
week than men. Men and women also had different
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Table 1 Baseline characteristics of participants included in the study (N = 598), SKIPOGH study (Switzerland, 2009–2013)
Men (n = 288) Women (n = 310) P-valuea, b
Age, mean (SD) 46.16 (17.41) 46.17 (17.28) 0.972
BMI (kg/m2), mean (SD) 25.84 (4.1) 24.08 (4.56) <0.001
Glomerular filtration rate, mean (SD) 97.46 (19.1) 95.68 (17.43) 0.116
Urinary parameters
Urinary volume (ml/24-h), mean (SD) 1751.38 (801.87) 1687.39 (682.89) 0.635
Urinary flow (ml/min), mean (SD) 1.23 (0.57) 1.19 (0.5) 0.663
Urinary creatinine (mg/kg/24-h), mean (SD) 22.33 (5.46) 18.35 (4.38) <0.001
Urinary caffeine (mg/24-h), median (IQR) 2.76 (3.61) 2.85 (4.03) 0.891
Urinary paraxanthine (mg/24-h), median (IQR) 11.33 (11.49) 9.43 (9.44) <0.001
Urinary theobromine (mg/24-h), median (IQR) 11.63 (12.78) 10.9 (11.95) 0.212
Urinary theophylline (mg/24-h), median (IQR) 0.95 (1.09) 0.89 (0.96) 0.347
Study center, n (%) 0.805
Lausanne 83 (29%) 97 (31%)
Geneva 101 (35%) 105 (34%)
Bern 104 (36%) 108 (35%)
Smoking, n (%) 0.024
No 212 (74%) 252 (81%)
Yes 76 (26%) 58 (19%)
Alcohol consumption, n (%) <0.001
No 62 (22%) 135 (44%)
Yes 226 (78%) 175 (56%)
Caffeinated coffee consumption 0.219
Never 23 (8%) 41 (13%)
1–4 times/month 15 (5%) 21 (7%)
1–4 times/week 18 (6%) 22 (7%)
≥ 5 times/week 11 (4%) 11 (4%)
≥ 1 time/day 221 (77%) 215 (69%)
Other caffeinated drink consumption, n (%) 0.755
Never 53 (18%) 56 (18%)
1–4 times/month 76 (26%) 88 (28%)
1–4 times/week 65 (23%) 59 (19%)
≥ 5 times/week 16 (6%) 14 (5%)
≥ 1 time/day 78 (27%) 93 (30%)
Decaffeinated coffee consumption, n (%) 0.004
Never 233 (81%) 210 (68%)
1–4 times/month 31 (11%) 62 (20%)
1–4 times/week 8 (3%) 15 (5%)
≥ 5 times/week 2 (1%) 6 (2%)
≥ 1 time/day 14 (5%) 17 (5%)
Data are mean (SD) or median (IQR) for continuous variables and N (%) for categorical variables
aMann–Whitney U test was performed between men and women for continuous variables
bChi2 contingency test was performed between men and women for categorical variables
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consumption patterns for decaffeinated coffee. Urinary
paraxanthine and theobromine excretions were higher
(more than 5 fold) than caffeine and theophylline in
both sex.
In Table 2 we show the adjusted medians of 24-h urin-
ary caffeine, paraxanthine, theophylline and theobromine
(winsorised 99th percentile), per consumption frequency
of caffeinated coffee, other caffeinated beverages, and
decaffeinated coffee for unadjusted and fully-adjusted
quantile regression models. We observed a positive
dose–response association between caffeinated coffee
consumption frequency and urinary caffeine (p-value for
trend <0.001, ρ = 0.473, p-value for ρ <0.001), paraxanthine
(p-value for trend <0.001, ρ = 0.528, p-value for ρ <0.001)
and theophylline (p-value for trend <0.001, ρ = 0.519, p-
value for ρ <0.001) in the unadjusted and the fully adjusted
models. We did not observe any significant association
between consumption frequencies of other caffeinated
beverages or decaffeinated coffee with any of the caffeine
derived metabolites.
In Fig. 1, we present ROC analysis results, including
AUC for the dichotomized caffeinated coffee consump-
tion frequency based on 24-h urinary excretions of
caffeine, paraxanthine, theophylline, and theobromine,
whereas related optimal cutoff and sensitivity/specificity
values are presented in Table 3. Optimal discrimination
between individuals who consumed less than one
caffeinated coffee per week versus at least one caffeinated
coffee, was obtained based on 24-h urinary paraxanthine
AUC = 0.868, 95% CI [0.830;0.906] with an optimal cutoff
at 2.582 mg, followed by theophylline AUC = 0.866, 95%
CI [0.827;0.904] (0.774 mg), and caffeine AUC = 0.849,
95% CI [0.808;0.891] (1.391 mg). Regarding theobromine,
AUC was 0.495, 95% CI [0.426;0.564], suggesting no
discrimination power.
To account for the fact that most of the participants
simultaneously consumed different types of caffeinated
beverages, we report in Additional file 1: Tables S1–S3
two-by-two combinations of consumption frequencies of
caffeinated coffee, decaffeinated coffee and other caffein-
ated beverages. Overall, we observed that consumption
of one type of beverage was generally associated with
the consumption of another beverage (p-value < 0.05).
Therefore, in order to examine 24-h metabolite excretion
resulting from the exclusive consumption of only one type
of beverage, we show in supplementary Additional file 1:
Tables S4-S5 median 24-h urinary excretions of caffeine,
paraxanthine, theophylline and theobromine by consump-
tion frequencies of either caffeinated coffee or other
caffeinated beverages, while the consumption frequency of
the remaining beverage and decaffeinated coffee was
“Never”. In Additional file 1: Table S4, despite an
extremely heterogeneous group size according to different
consumption frequencies, we observed an almost step-
wise increase in 24-h urinary excretion of caffeine, para-
xanthine and theophylline as the consumption frequency
of caffeinated coffee increased, which is in line with results
presented in Table 2. In Additional file 1: Table S5, we also
observed an increasing 24-h urinary excretion of all four
caffeine derived metabolites as the consumption frequency
of other caffeinated beverages increased.
Discussion
In this population-based Swiss study, we found a strong
association between reported consumption of caffeinated
coffee and 24-h urinary excretion of paraxanthine, theo-
phylline and caffeine, which is in line with previous re-
search [19–22]. Our results suggest that self-reported
consumption with the question “How often do you con-
sume caffeinated coffee?”- could be used as a proxy of
caffeine exposure, if no caffeine derived metabolites are
available. The information gathered from self-reported
consumption of caffeine intake is reliable enough to
highlight associations between caffeine intake and major
phenotypes or outcomes [10, 24, 34]. With the exception
of theobromine, ROC analysis also showed that the 24-h
urinary excretions of paraxanthine, theophylline and caf-
feine discriminated well weekly self-reported consump-
tion frequency of caffeinated coffee.
Regarding the association between caffeinated coffee
intake and urinary excretion of caffeine derived metabo-
lites, our results are in line with previous studies that
tested the use of caffeine derived metabolites in urine,
serum or umbilical cord blood, as a potential marker of
self-reported caffeine intake [19–21]. While there were
important methodological differences in terms of assess-
ment of self-reported caffeine intake, metabolite measure-
ments or population characteristics between our study
and this previous research, the correlation coefficients for
the association between caffeinated coffee intake or self-
reported intake of total caffeine [19–21] and 24-h urinary
excretion caffeine, paraxanthine and theophylline, were
generally in the same order of magnitude, ranging be-
tween 0.4 and 0.6. Thus, the adjusted medians of urinary
caffeine, paraxanthine, and theophylline were the lowest
among participants reporting never consuming caffeinated
coffee and the highest among participants reporting the
highest intake of this beverage. These results are in line
with previous research showing that caffeinated coffee
constitutes the main source of measured caffeine and
caffeine metabolites in both urine and serum [24, 35].
Theobromine levels did not differ across intake,
which might be due to the fact that theobromine is
mostly found in chocolate [36].
Conversely, consumption frequencies of other caffein-
ated beverages and decaffeinated coffee were not associ-
ated with urinary excretions of caffeine or any of the
other caffeine metabolites. Of note, the median levels of
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Table 2 Adjusted medians for 24-h excreted urinary metabolites [mg] according to the consumption frequencies of caffeinated
coffee, other caffeinated beverages and decaffeinated coffee (quantile regression)
Never 1–4×/Month 1–4×/Week 5×/Week > = 1×/day P for trenda ρc Pd
Adjusted medians for 24-h urinary caffeine [mg] (winsorised 99th percentile)
Caffeinated coffee
Unadjusted model 0.791 1.270 1.890 2.469 3.612 <0.001 0.473 <0.001
Fully adjusted modelb 1.382 1.655 2.262 2.959 3.724 <0.001
Other caffeinated drinks
Unadjusted model 3.144 3.116 2.521 1.787 2.954 0.578 −0.069 0.090
Fully adjusted modelb 3.419 3.285 3.034 1.899 3.268 0.702
Decaffeinated coffee
Unadjusted model 2.694 2.842 2.787 6.576 3.128 0.374 0.039 0.346
Fully adjusted modelb 3.273 2.929 3.022 4.586 3.032 0.612
Adjusted medians for 24-h urinary paraxanthine [mg] (win. 99th perc.)
Caffeinated coffee
Unadjusted model 2.331 4.269 6.833 6.923 12.512 <0.001 0.528 <0.001
Fully adjusted modelb 3.847 4.287 7.174 8.755 12.456 <0.001
Other caffeinated drinks
Unadjusted model 12.361 9.993 8.706 8.361 10.706 0.469 −0.061 0.133
Fully adjusted modelb 12.781 10.506 9.368 8.533 11.150 0.185
Decaffeinated coffee
Unadjusted model 9.875 9.571 9.500 17.852 11.407 0.324 0.057 0.164
Fully adjusted modelb 10.498 10.271 10.188 11.503 11.829 0.494
Adjusted medians for 24-h urinary theophylline [mg] (win. 99th perc.)
Caffeinated coffee
Unadjusted model 0.266 0.353 0.660 0.689 1.163 <0.001 0.519 <0.001
Fully adjusted modelb 0.347 0.396 0.603 0.835 1.145 <0.001
Other caffeinated drinks
Unadjusted model 1.036 1.007 0.734 0.724 0.935 0.093 −0.075 0.069
Fully adjusted modelb 1.100 0.982 0.842 0.684 0.965 0.519
Decaffeinated coffee
Unadjusted model 0.870 1.034 0.683 1.406 1.081 0.155 0.040 0.329
Fully adjusted modelb 0.933 0.901 0.749 1.563 0.923 0.972
Adjusted medians for 24-h urinary theobromine [mg] (win. 99th perc.)
Caffeinated coffee
Unadjusted model 11.352 12.911 13.743 11.747 10.977 0.398 −0.019 0.637
Fully adjusted modelb 10.361 11.231 13.992 11.286 11.949 0.726
Other caffeinated drinks
Unadjusted model 11.900 10.287 11.456 10.904 11.623 0.870 0.013 0.746
Fully adjusted modelb 13.256 11.203 10.854 9.342 13.351 0.472
Decaffeinated coffee
Unadjusted model 10.889 12.125 11.773 11.097 12.369 0.445 0.045 0.271
Fully adjusted modelb 11.588 12.635 11.056 9.516 14.604 0.178
aP-value for linear trend (Reported consumption frequency: lowest vs. highest)
bModel was adjusted for age, sex, BMI, urinary creatinine, glomerular filtration rate, urinary volume, urinary flow, study center, smoking and alcohol status
cSpearman correlation coefficient (ρ) for the association between self-reported consumption frequency and 24-h urinary excretion
dSpearman correlation coefficient associated p-value
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caffeine, paraxanthine, and theophylline were higher
among participants who reported “never other caffeinated
drinks” or “never decaffeinated coffee” compared to par-
ticipants who reported “never caffeinated coffee”. This can
be largely explained by the fact that the majority of partici-
pants in the “never other caffeinated drinks” or “never
decaffeinated coffee” groups reported very frequent caf-
feinated coffee intake (Additional file 1: Tables S1–S3).
Therefore, the absence of association in Table 2 between
consumption frequency of other caffeinated beverages and
24-h urinary caffeine, paraxanthine and theophylline, is
likely due to the caffeine input of caffeinated coffee con-
sumption, which may mask the caffeine input from other
caffeinated beverages only and therefore affect the 24-h
urinary metabolite excretion trend. Thus, once caffeine in-
put by caffeinated coffee and decaffeinated coffee is ex-
cluded (Additional file 1: Table S5), a clear positive trend
is observed between increasing frequency of other
caffeinated beverages and 24-h urinary excretion of all
four metabolites. We may assume that a positive
trend might also be observed for an increasing con-
sumption frequency of decaffeinated coffee as this
beverage also contains a certain amount of caffeine
[37], yet due to the total lack of participants for
several consumption frequencies of exclusive decaf-
feinated coffee intake, this couldn’t be assessed here.
Regarding ROC analysis, the observed AUC values
were in line with the results from quantitative regres-
sion. The strongest AUCs were observed for 24-h
urinary paraxanthine, whereas there was no relation for
24-h urinary theobromine, supporting the fact that urin-
ary paraxanthine is likely the most common metabolite
of caffeine intake [38, 39]. Our results thus suggest that
paraxanthine may be used as a gold standard in future
analyses investigating the validity of coffee consumption
based on other urinary metabolites.
Strengths and limitations
This is, to our knowledge, the first study to investigate
the association between consumption frequency of three
different common drinks (caffeinated coffee, other
caffeinated beverages, decaffeinated coffee) and the 24-h
excretion of caffeine and three caffeine metabolites, in a
population based study.
Fig. 1 Receiver Operator Characteristic (ROC) curves for weekly dichotomized self-reported caffeinated coffee consumption, based on 24-h urinary
caffeine, paraxanthine, theophylline, theobromine (win: 99th percentile winsorised). Sensitivity, specificity and cutoff points are reported in Table 3.
AUC: Area under curve [95% CI]
Table 3 Optimal sensitivity, specificity and cutoff points for
weekly caffeinated coffee consumption based on 24-h urinary
metabolites – ROC analysis (Fig. 1)
Sensitivity Specificity Cutoff (mg)
24-h urinary metabolite
24-h urinary caffeine 0.723 0.840 1.391
24-h urinary paraxanthine 0.801 0.790 2.582
24-h urinary theophylline 0.787 0.800 0.774
24-h urinary theobromine 0.938 0.160 1.665
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Our study has several limitations. First, the question-
naire on caffeine reflects local food habit. Previous investi-
gations have suggested large national differences regarding
consumption habits of caffeinated coffee, tea, soft drinks
or energy drinks [40–43]. Consequently, our results might
not be generalized to settings with different food habits.
Second, the validity of 24-h urine excretion is known to
depend on the quality of urine collection. We therefore
adjusted our analyses for urinary creatinine and volume.
Third, while we account for major potential confounders,
residual confounding cannot be excluded and information
on other potential confounders (e.g. CYP1A2 gene, liver
function) was not available. Information on self-reported
liver diseases, including malignant liver cancer, liver
cirrhosis, chronic liver disease or unspecified liver dis-
orders, was collected but none of the included partic-
ipants reported any of the four liver-related disorders.
Furthermore, we must also take into account that the
questionnaire used here is not a 24-h dietary recall or
3 days-diet diary, it may therefore introduce bias be-
cause of the recalling abilities of the participants.
Fourth, the results of the present study are based on
observational data, thus, an intervention or an experimen-
tal approach shall be considered in order to further
explore and validate the association between caffeinated
beverage intake and 24-h urinary excretion.
Conclusion
Our results suggest that there is a strong association
between reported consumption of caffeinated coffee and
24-h urinary caffeine metabolites. The associations between
reported consumption of other caffeinated drinks/decaf-
feinated coffee and 24-h urinary excretions are less clear.
Finally, urinary paraxanthine appeared to best discriminate
individuals who consumed less than one caffeinated coffee
per week versus individuals who consumed more.
Additional file
Additional file 1: Table S1. Reported consumption frequencies of
caffeinated and decaffeinated coffee N (%). Table S2. Reported
consumption frequencies of other caffeinated beverages and decaffeinated
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